康弘药业KH816注射液临床试验获批

Core Viewpoint - Kanghong Pharmaceutical announced that its wholly-owned subsidiary, Chengdu Kanghong Biotechnology Co., Ltd., received approval from the National Medical Products Administration for clinical trials of KH816 injection, a biosimilar of Dupilumab, targeting moderate to severe atopic dermatitis in adults [1]. Group 1 - The approval allows for the clinical trial of KH816 injection [1] - KH816 is developed as a biosimilar to Dupilumab [1] - The targeted clinical indication is for adult patients with moderate to severe atopic dermatitis [1]